Sign in
Taking people in United StatesNo phase

Testing a longer-lasting device therapy for restless legs syndrome

Tests safety of a new device for restless legs syndrome.

Key facts

Who runs it
Noctrix Health, Inc.
Where
Pleasanton, United StatesSee the site
Trial code
Registry title
Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS)
Status
Recruiting
People taking part
20 people, planned
Started
8 Jun 2026
Expected to end
Jun 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Investigational Extended Duration (XD-) TOMAC Therapy
  • Tonic Motor Activation (TOMAC) Therapy
Record updated
30 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with primary restless legs syndrome (RLS) who have moderate to severe symptoms that disturb their sleep. They will test a new device worn on the legs that does not go into the body.

Age
21 years or older
Sex
All sexes
Disease stage
Primary RLS with moderate to severe symptoms, a score of 15 or more on the IRLS scale. Symptoms are worst in the lower legs and/or feet. In the month before entry, symptoms woke the person or kept them from falling back asleep at least 3 nights per week.
Earlier treatment
No change in dose or schedule of medicines or treatments that affect RLS or sleep (such as RLS medicines, antidepressants, sleep medicines, sedative antihistamines or CPAP) in the past 30 days. These must stay unchanged during the study. People who have used the sponsor's nerve stimulation devices before cannot join.

Main reasons for not taking part

  • An active implanted device such as a pacemaker or spinal cord or brain stimulator, or a metal implant where the device goes (knee replacements are allowed)
  • Epilepsy or another seizure disorder
  • Another main sleep disorder that strongly disturbs sleep now, or a sleep schedule not mostly at night (for example shift work)
  • Severe nerve damage (neuropathy) in the lower legs, or not being able to tell neuropathy symptoms apart from RLS
  • Allergy to device materials, electrode gel, polyurethane foam or lycra, or injury, cellulitis or open sores where the device goes

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Subject has signed a valid, IRB-approved informed consent form, can understand the requirements of the study and instructions for device usage, and can converse in English
  • Subject has received a medical diagnosis of primary restless legs syndrome (RLS)
  • Subject agrees to not change dosage or schedule of any medications that are known to impact RLS symptoms during the study, including RLS medications, antidepressants, sleep medications, or sedative antihistamines or treatments such as CPAP (continuous positive airway pressure)
  • Subject reports that RLS symptoms are most significant in lower legs and/or feet
  • Subject reports that RLS symptoms caused awakenings or interfered with falling back asleep at least 3 nights per week during the month prior to study entry
  • The subject possesses the necessary equipment, internet/phone accessibility, and communication ability to complete electronic questionnaires and respond to electronic communications and phone calls from the research staff throughout the in-home portion of the study
  • Subject has moderate-severe RLS symptoms as defined by a score of 15 or greater points on IRLS (International Restless Legs Syndrome Study Group Rating Scale)
  • Subject is 21 years of age or older

Who cannot take part

  • The subject has an active medical device implant anywhere in the body (including but not limited to pacemakers, spinal cord stimulators, deep brain stimulators)
  • The subject has a metal implant at the site of the study device electrode application (not including knee replacements)
  • The subject has a known allergy to device materials, electrode gel, polyurethane foam, or lycra (or a severe previous reaction to medical adhesives or bandages)
  • Subject has prior experience with neurostimulation devices developed by the study sponsor
  • Subject is taking an unstable or inconsistent dose or schedule of medication that is likely to impact RLS symptoms or sleep, such as RLS medications, antidepressants, sleep medications, or sedative antihistamines
  • Subject has changed dose or schedule of medication or treatment that is likely to impact RLS symptoms or sleep in the past 30 days, such as RLS medications, antidepressants, sleep medications, or sedative antihistamines or treatments such as CPAP
  • The subject has been diagnosed with epilepsy or other seizure disorder
  • The subject has a moderate or severe cognitive disorder or mental illness that would affect his or her ability to participate in the study
  • The subject has a medical condition not listed above that may put them at risk
  • Subject has a primary sleep disorder other than RLS that significantly interferes with sleep at the present time (e.g. obstructive sleep apnea stably controlled via CPAP would not be an exclusion)
  • Subject has any of the following at or near the location of device application: Acute injury, Cellulitis, Open sores
  • The subject is unable or unwilling to comply with study requirements
  • On nights with no RLS symptoms (if any), subject reports typical sleep onset latency of >60min
  • Subject has severe peripheral neuropathy affecting the lower legs and/or subject has neuropathy and is unable to clearly distinguish between symptoms of neuropathy and symptoms of RLS
  • Subject reports a habitual sleep schedule that is not primarily aligned with nighttime hours (bedtime 8:00pm-2:00am and morning awakening 4:00am-11:00am), or reports that bedtime regularly varies by more than 4 hours (e.g., due to shift work or an inconsistent sleep schedule)
  • During initial device set-up, device does not properly fit the subject or calibrated intensity settings are outside of operational range

Where in United States

  • Noctrix Health HeadquartersPleasanton, United StatesContact: Clinical Research CoordinatorTaking people

About the trial

What the trial wants to find out

This study assesses the tolerability, safety, and impact of an investigational medical device on restless legs syndrome symptoms.

Read full original descriptionShow less

The IRB has established that the investigational device is non-significant risk.

The 3 groups in the trial

  • Investigational XD-TOMAC Therapy 1Treatment being tested

    Participants will use investigational noninvasive neuromodulation device for XD-TOMAC therapy as instructed for 3, 2-week periods over the final 6-weeks of the study. The XD-TOMAC therapy settings may change for each of the 2-week periods in a pseudo-randomized order. Investigational XD-TOMAC settings may include different methods for modulating the stimulation waveform.

    Treatment: Investigational Extended Duration (XD-) TOMAC Therapy and Tonic Motor Activation (TOMAC) Therapy

  • Investigational XD-TOMAC Therapy 2Treatment being tested

    Participants will use investigational noninvasive neuromodulation device for XD-TOMAC therapy as instructed for 3, 2-week periods over the final 6-weeks of the study. The XD-TOMAC therapy settings may change for each of the 2-week periods in a pseudo-randomized order. Investigational XD-TOMAC settings may include different methods for modulating the stimulation waveform.

    Treatment: Investigational Extended Duration (XD-) TOMAC Therapy and Tonic Motor Activation (TOMAC) Therapy

  • Investigational XD-TOMAC Therapy 3Treatment being tested

    Participants will use investigational noninvasive neuromodulation device for XD-TOMAC therapy as instructed for 3, 2-week periods over the final 6-weeks of the study. The XD-TOMAC therapy settings may change for each of the 2-week periods in a pseudo-randomized order. Investigational XD-TOMAC settings may include different methods for modulating the stimulation waveform.

    Treatment: Investigational Extended Duration (XD-) TOMAC Therapy and Tonic Motor Activation (TOMAC) Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Form, Fit and Function Feasibility Study
Plain-language title
Testing a longer-lasting device therapy for restless legs syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
30 June 2026